Effects of risedronate on fracture risk in postmenopausal women with osteopenia

[1] Siris ES(2001)Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment JAMA 286 2815-2822

[2] Miller PD(2004)Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study Bone 34 195-202

[3] Barrett-Connor E(2005)Hip fracture in women without osteoporosis J Clin Endocrinol Metab 90 2787-2793

[4] Schuit SC(2005)Identification of osteopenic women at high risk of fracture: the OFELY study J Bone Miner Res 20 1813-1819

[5] van der Klift M(2006)Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? Bone 38 694-700

[6] Weel AE(2004)An approach to identifying osteopenic women at increased short-term risk of fracture Arch Intern Med 164 1113-1120

[7] Wainwright SA(2002)Diagnosis of osteoporosis and assessment of fracture risk Lancet 359 1929-1936

[8] Marshall LM(2002)Uncertain future of trials in osteoporosis Osteoporos Int 13 443-449

[9] Ensrud KE(2000)Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group J Clin Endocrinol Metab 85 1895-1900

[10] Sornay-Rendu E(1998)Risedronate increases bone mineral density at the hip, spine and radius in postmenopausal women with low bone mass Osteoporos Int 8 111-91

[1] Siris ES(2001)Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment JAMA 286 2815-2822

[2] Miller PD(2004)Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study Bone 34 195-202

[3] Barrett-Connor E(2005)Hip fracture in women without osteoporosis J Clin Endocrinol Metab 90 2787-2793

[4] Schuit SC(2005)Identification of osteopenic women at high risk of fracture: the OFELY study J Bone Miner Res 20 1813-1819

[5] van der Klift M(2006)Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? Bone 38 694-700

[6] Weel AE(2004)An approach to identifying osteopenic women at increased short-term risk of fracture Arch Intern Med 164 1113-1120

[7] Wainwright SA(2002)Diagnosis of osteoporosis and assessment of fracture risk Lancet 359 1929-1936

[8] Marshall LM(2002)Uncertain future of trials in osteoporosis Osteoporos Int 13 443-449

[9] Ensrud KE(2000)Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group J Clin Endocrinol Metab 85 1895-1900

[10] Sornay-Rendu E(1998)Risedronate increases bone mineral density at the hip, spine and radius in postmenopausal women with low bone mass Osteoporos Int 8 111-91